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ABSTRACT 
Chlamydiae are obligate intracellular Gram-negative bacteria with a unique 
biphasic developmental cycle, alternating between infectious elementary bodies and 
replicative reticulate bodies. However, when exposed to stressful conditions such as 
iron deprivation and IFN-γ exposure, they fail to complete their developmental cycle 
generating morphologically aberrant reticulate bodies called persistent forms, which 
remain viable but non-infectious inside the host-cell for a long time and are difficult 
to eradicate with antibiotics. Chlamydiae cause a broad spectrum of diseases. 
Chlamydia pneumoniae causes community-acquired pneumonia and other respiratory 
tract infections, while Chlamydia trachomatis is the leading cause of sexually 
transmitted diseases all over the world and of trachoma in developing countries. More 
importantly, these pathogens may cause chronic sequelae. In fact, C. pneumoniae 
infections may be associated to atherosclerosis, whereas C. trachomatis infections lead 
to ectopic pregnancy, obstructive infertility and reactive arthritis. These sequelae could 
result from the inflammatory state induced by the persistent forms. 
In our research, we studied in vitro different aspects of chlamydial 
pathogenesis and treatment in C. pneumoniae and C. trachomatis, achieving the 
following results. In C. pneumoniae, in order to investigate the atherogenic process, 
we set up a model of foam cell induction by means of macrophages infection. In this 
model, we highlighted for the first time the C. pneumoniae-dependent production of 
IL-17A, a cytokine recently reported as proatherogenic. Moreover, we investigated the 
protective effects of resveratrol, a natural polyphenol known to exert antioxidant, 
cholesterol-lowering and anti-inflammatory effects. Resveratrol is able to avoid foam 
cell formation in macrophages exposed to high levels of lipoproteins, with possible 
applications in the prevention of atherosclerosis. In C. trachomatis, we assessed the 
antichlamydial activity of the essential oil of Mentha suaveolens, in an effort to find 
out new means to prevent sexually transmitted diseases. 
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1 INTRODUCTION 
1.1 A brief history of Chlamydiae 
Chlamydiae are obligate intracellular microorganisms, non-motile, non-spore 
forming, unable to live in the extracellular environment because they cannot produce 
and store energy (as adenosine triphosphate, ATP). The cellular structure of 
Chlamydiae is very similar to that of Gram-negative bacteria and although these 
microorganisms multiply by binary scission like other bacteria, they undergo a 
characteristic development cycle alternating two functionally and morphologically 
distinct forms: the elementary body and the reticulate body. 
The name chlamydia derives from the Greek word klamis, which means 
mantle, and it is due to the presence of a thick vacuolar membrane, which surrounds 
chlamydial microcolonies in the host cell cytoplasm. Initially, Chlamydiae were 
considered as distinct and unrelated microorganisms rather than a single family 
because of the different medical cases, anatomical localisations, clinical symptoms and 
transmission routes that characterise them. 
In 1890, sporadic cases of pneumonia were reported in traders and owners of 
exotic birds and, later, in 1907 the etiology of trachoma, which is a serious conjunctival 
infection known since ancient times (ancient Egyptians knew it since XVI century BC 
and even before Chinese had already known it from XXVII century BC), was 
attributed to Chlamydiae. In 1911, were observed cases of “inclusion conjunctivitis” 
associated with genital tract infections. In the years 1929-1930, following an outbreak 
of atypical pneumonia, studies focused on this disease began so that it was recognised 
as infectious. The causative agent was called Rickettsia psittaci and psittacosis the 
disease. Later, it was distinct from rickettsial agents, bacteria which live as obligate 
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intracellular parasites, for the fact of not being parasitic of invertebrates and therefore 
to not be transmitted to animals or humans through a vector. 
Their obligate intracellular parasitism, their small size, their inability to grow 
on common culture media are features, which initially lead to the misidentification of 
Chlamydiae as unusually large viruses. The thirties and forties were a milestone in the 
history of Chlamydiae classification, because in those years began the first studies on 
trachoma and other diseases caused by these microorganisms (Eichmann, 1988). In 
this way, in 1966 it was possible to classify Chlamydiae as belonging to a single genus 
based on morphological and reproductive similarities that exist between the various 
species (Moulder, 1966; Page, 1966). Later, Storz and Page (1971) introduced the 
order Chlamydiales and two species: Chlamydia trachomatis and Chlamydia psittaci. 
In the following years have been recognised new families, genera and species. 
In particular, information about the existence of strains of Chlamydia 
pneumoniae date back to 1943, when Smadel and colleagues described cases of 
pneumonia through the complement fixation test for psittacosis, in patients who had 
never been in contact with birds. It was initially thought to a strain of C. psittaci 
transmitted to humans. Later, in 1958 and 1960 were recorded cases of epidemic 
ornithosis in Finland (Allegra, 1995). In 1965 was isolated in Taiwan, from the 
conjunctiva of a child during the trachoma vaccine study, an unusual strain of 
Chlamydia called TW-183 (Grayston et al., 1986). Two years later, in Iran was 
isolated, from the conjunctiva of children, a strain of Chlamydia referred as IOL-207 
(Dwyer et al., 1972). In 1978 in Finland, during an outbreak of pneumonia, was 
highlighted the presence of IgM antibodies directed against TW-183 (Saikku et al., 
1985). From 1983 to 1986 in Seattle (USA) were isolated from throat swabs of patients 
with acute respiratory diseases, 12 strains of Chlamydia designated AR and LR 
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(Grayston et al., 1986) and after the union of the two acronyms, TW and AR, the 
strains were called TWAR (Taiwan Acute Respiratory). 
Later, in 1989, after ultrastructural analysis and investigations about sequence 
homology of their genome, it was shown that TWAR strains have characteristics such 
as to be classified as a new species named Chlamydia pneumoniae, initially assigned 
to the genus Chlamydia and more recently to the new genus Chlamydophila (Grayston 
et al., 1989; Everett et al., 1999a) together with C. psittaci. However, the 
establishment of this new genus has not been universally accepted and both names are 
currently in use. 
1.2 Classification 
Until 1999, the classification of Chlamydiae was mainly based on 
morphological and phenotypic traits. The classification has recently undergone major 
changes on the basis of results obtained by the sequence analysis of the genes coding 
for ribosomal RNA (Grayston et al., 1989; Everett et al., 1999a; Bush & Everett, 
2001). According to the previous classification, Chlamydiae belonged (Table I) to the 
order Chlamydiales, the family Chlamydiaceae and the genus Chlamydia which 
included four species: Chlamydia psittaci, Chlamydia trachomatis, Chlamydia 
pneumoniae and Chlamydia pecorum. 
According to the current classification (Table I), four families were assigned to 
the order Chlamydiales: Chlamydiaceae, Parachlamydiaceae, Waddliaceae and 
Simkaniaceae but more recently have been proposed additional families. Currently, 
two distinct genera belong to the family of Chlamydiaceae: Chlamydia and 
Chlamydophila. 
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TABLE I. The order Chlamydiales: the recent taxonomic revision compared to the original classification (freely adapted from 
Bush & Everett, 2001). 
   Typical host  
Chlamydiales 
Chlamydiaceae 
     
Chlamydiales 
Chlamydiaceae 
Chlamydophila  Chlamydia 
C. abortus mammals  
C. psittaci birds C. psittaci 
C. felis cats  
C. caviae Guinea pigs  
C. pecorum mammals C. pecorum 
C. pneumoniae humans C. pneumoniae 
   
Chlamydia   
C. trachomatis humans C. trachomatis 
C. suis swine  
C. muridarum mice, hamsters  
    
Parachlamydiaceae    
Waddliaceae    
Simkaniaceae    
      
New classification  Old classification 
 
The genus Chlamydia includes three species: Chlamydia trachomatis, 
Chlamydia muridarum and Chlamydia suis. C. suis has been isolated only from pigs, 
in which it causes conjunctivitis, purulent rhinitis, enteritis, pneumonia and 
bronchopneumonia. C. muridarum is the name given to two strains of bacteria isolated 
from mice and hamsters respectively. C. trachomatis, unlike the other two species of 
Chlamydia, is a strictly human pathogen, infects predominantly the conjunctival 
epithelium and the genital tract, thus causing infections in different apparatuses. 
The genus Chlamydophila brings together the current species Chlamydia 
pecorum, Chlamydia pneumoniae and Chlamydia psittaci respectively called 
Chlamydophila pecorum, Chlamydophila pneumoniae and Chlamydophila psittaci 
along with three new species, separated from the original C. psittaci and called 
Chlamydophila caviae, Chlamydophila abortus and Chlamydophila felis (Garrity 
et al., 2001; Grayston et al., 1989, Everett et al., 1999a; Bush & Everett, 2001). 
C. pneumoniae is an important agent of pneumonia in humans, and it has no known 
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reservoir in other mammals or birds, therefore, it is a strictly human pathogen like 
C. trachomatis and unlike the other species of Chlamydophila. 
1.3 Morphology and cellular organisation 
Chlamydiae present a cellular organisation similar to that of Gram-negative 
bacteria which differs mainly due to the lack of muramic acid and consequently of 
peptidoglycan in their cell wall (Ghuysen & Goffin, 1999; McCoy & Maurelli, 2006). 
An outer membrane and an inner membrane, delimiting a periplasmic space (Figure 
1), constitute the cell wall of both elementary and reticulate bodies. 
 
FIGURE 1. The current model of the envelope of chlamydial EBs (freely adapted from Hatch, 1996) showing only MOMP, large 
and small CRPs in the outer membrane and the periplasm, even though many other proteins are probably located there. The 
presence of a P layer, presumably consisting entirely of cross-linked large CRPs, has been confirmed by electron microscopy. 
The outer membrane is composed of phospholipids (oriented in the inner wall 
to form a hydrophobic layer), lipopolysaccharide (oriented in the outer wall to form a 
hydrophilic layer) and lipoproteins. The lipopolysaccharide (LPS) is the major 
constituent of the outer membrane and appears approximately 30 hours after infection, 
in conjunction with the maturation of the inclusions, persists for the duration of the 
replicative cycle and is able to be embedded in the host cell membrane (Hatch, 1996; 
Brade, 1999). 
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LPS consists of an oligosaccharide core, the hydrophilic portion, known as 
keto-deoxyoctulosonate (KDO) region, from which originate antigenic polysaccharide 
chains and a lipid component, the hydrophobic portion, referred as lipid A. KDO 
region is essential for the survival of the bacterium, while lipid A represents the 
effective endotoxin. In particular, lipid A of C. pneumoniae possesses three epitopes 
similar to those identified in the lipopolysaccharide of other gram-negative bacteria, 
while the composition in terms of fatty acids is much more similar to that of 
C. trachomatis and C. psittaci. However, it differs from other Chlamydiales for the 
presence of long-chain fatty acids ranging from 22 to up 26 carbon atoms (Hatch, 
1996). 
The outer membrane proteins (OMPs) together constitute the so-called 
complex of the outer membrane, which includes the following components: major 
outer membrane protein (MOMP), cysteine-rich proteins (CRPs) and heat-shock 
proteins (HSPs). 
MOMP, which has a molecular weight of 39.5 kDa (ranging from 38 to 
42 kDA), represents about 60% by weight of the proteins in the outer membrane 
(Caldwell et al., 1981; Caldwell & Schachter, 1982). MOMP is a transmembrane 
protein containing four variable protein domains. This protein provides for the 
maintenance of the structural integrity of the membrane. In fact, each molecule of 
MOMP possesses at least three cysteine residues that, through disulfide bonds, are 
linked to other MOMP molecules and two CRPs to form aggregates (Newhall, 1987). 
In this regard, it had been initially proposed a model with a hexagonal structure that 
consisted of six MOMP dimers arranged around a central core (Chang et al., 1982). 
Moreover, MOMP has the function of a porin (with an exclusion limit of 850-2250 
Da) allowing the passive diffusion of hydrophilic compounds according to their 
concentration gradients (Bavoil et al., 1984). Indeed, freeze-fracture studies have 
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highlighted the presence of a transmembrane channel (Louis et al., 1980) which has 
been proposed to be responsible for the porin function. Overall, the best model 
available to date is that of a trimeric porin unit constituted predominatly of a β-sheet 
structure (Sun et al., 2007). However, the actual structure of chlamydial MOMP 
remains elusive since the attempts to obtain X-ray crystals with native MOMP proteins 
have been unsuccessful, so the current knowledge comes from indirect studies and 
computational modelling (Feher et al., 2013). 
CRPs with a molecular weight of 12 kDa (OMP3) and 60 kDa (OMP2), are 
responsible for the rigidity of the membrane due to the high number of intramolecular 
disulfide bonds which are able to form (Hatch, 1996). OMP3 (also called OmcA or 
EnvA) and OMP2 (also called OmcB or EnvB) are proteins that are common to all the 
species belonging to the family Chlamydiaceae (Everett & Hatch, 1995). In particular, 
OMP3 is a cysteine-rich lipoprotein anchored to the outer membrane through its 
lipophilic portion, while the hydrophilic segment extends to the periplasm (Hatch, 
1996). OMP3 probably interacts with the host cell in the process of adhesion, by means 
of an amino acid sequence exposed on its hydrophilic surface. 
HSPs represent a family of proteins synthesized 8-10 hours after chlamydial 
infection, and are involved in the preparation and assembly of proteins into multimeric 
complexes (Kuo et al., 1995). These proteins are expressed throughout the lifetime of 
the replicative cycle, at least for C. pneumoniae (Kuo et al., 1995). The most studied 
is the 60 kDa HSP (HSP60), which is responsible for hypersensitivity reactions, cross-
reactivity and immunopathogenesis in chlamydial infections (Kuo et al., 1995). While, 
HSP75 is synthesized later during the replicative cycle and is a cytoplasmic protein. 
Furthermore, in the membrane of the inclusions is present a group of 
membrane-associated proteins, called Inc (Subtil et al., 2001). These proteins may be 
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involved in the vesicular interactions with the host cell, the development of the 
inclusion, the avoiding of the lysosomal fusion, the acquisition of nutrients and signals 
associated with the differentiation of reticulate bodies into elementary bodies and vice 
versa (Scidmore et al., 1996; Wyrick, 2000; Subtil et al., 2001). 
1.4 Antigenic structure 
The antigenic structure of the Chlamydiaceae is characterised by the presence 
of various antigens, which are either genus-, species- or serotype-specific. The genus-
specific antigen, common to all Chlamydiae, is of polysaccharide nature and 
thermolabile, is associated to the cell wall of both elementary and reticulate bodies, 
and more specifically is represented by LPS (Brade et al., 1987). 
The polysaccharide portion of LPS presents two epitopes, one similar to that 
of Enterobacteriacea and the other specific to the family Chlamydiaceae, while the 
lipid portion presents three epitopes similar to those located on LPS of other bacteria 
(Schramek et al., 1980; Halme & Surcel, 1997). The most important antigenic group 
of LPS is represented by 2-keto-3-dioxaoctanoic acid (Subtil et al., 2001; Nurminen 
et al., 1983). But in addition to LPS were highlighted other genus-specific antigens in 
C. pneumoniae such as proteins with molecular weight of 12 and 26 kDa, and those 
ranging from 46 to 49 and from 65 to 70 kDa (Campbell et al., 1990). 
MOMP presents species-specific epitopes and, in fact, the sequence homology 
between the different species belonging to the family Chlamydiaceae is rather low 
(Kuo et al., 1995), moreover several studies have shown that C. pneumoniae MOMP 
is less immunogenic than that of the other species. The low immunogenic power of 
C. pneumoniae MOMP, associated with a limited cross-reactivity with MOMPs of the 
other species, suggests that MOMP should present at least some genus-specific 
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antigenic determinants (Kuo et al., 1995). However, unlike the case of C. trachomatis 
where the genetic variability of MOMP leads to a clear division into serogroups, the 
ompA gene in C. pneumoniae appears to be highly conserved (Jantos et al., 1997). 
In fact, C. trachomatis is subdivided into three biological variants (biovars): 
trachoma, lymphogranuloma venereum (LGV) and mouse pneumonitis (MoPn) 
agents. The first two biovars have been further separated into 15 serological variants 
(serovars) according to Wang and Grayston (1970): L1, L2 and L3 which cause LGV; 
A, B, Ba and C which are associated with trachoma whereas serovars D through K are 
commonly associated with sexually transmitted infections. However, the reliability of 
this distinction appears to be limited because, as highlighted by Byrne (2010), there is 
evidence that MOMP serovars fail to show relationships to virulence thus it is critical 
to extend studies beyond this paradigm. 
In addition to MOMP, have been associated to the complex of the outer 
membrane also CRPs with a molecular weight of 98, 60 and 15.5 kDa (Kuo et al., 
1995). The latter two proteins are similar in molecular weight and structure, to the 
proteins of the other Chlamydiaceae, while the 98 kDa protein is present exclusively 
in the complex of the outer membrane of C. pneumoniae (Campbell et al., 1990; Iijima 
et al., 1994; Kuo et al., 1995). 
Many other antigens have been described so far, they are mainly species-
specific proteic antigens or serotype-specific thermolabile antigens associated with 
MOMP, which are able to induce an immunogenic response. 
In any case, even though Chlamydiae have many antigens in common, there 
are differences between the antigens of elementary bodies and those of reticulate 
bodies. 
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1.5 Development cycle 
Chlamydiae have a quite limited metabolic capacity of energy production. This 
feature forces the bacterium to intracellular parasitism, while being capable of 
synthesizing macromolecules such as RNA and DNA autonomously. Chlamydiae take 
from the host cell not only ATP and other triphosphate cofactors (eg.: nicotinamide 
nucleotide, coenzyme A, etc.) necessary for the metabolism and replication but also 
amino acids, nucleotides and other precursors (Hackstdat, 1997; Greub et al., 2003). 
However, it has been recently suggested that Chlamydiae are also capable of 
independently producing energy, since they possess a nearly complete tricarboxylic 
acid (TCA), glycolysis and pentose phosphate pathways for glucose catabolism 
(Vandahl et al., 2001; Maurer et al., 2007; Saka et al., 2011). 
The characteristic that distinguishes Chlamydiae from all other bacteria is the 
mode of development, which occurs within the host cell where the microorganism is 
capable of alternating between two functionally and morphologically distinct forms 
(Figure 2): the elementary body (EB) and the reticulate body (RB) (Matsumoto, 1988; 
Rockey & Matsumoto, 2000). The main stages of the development cycle are as 
follows: adhesion, penetration, inhibition of lysosomal fusion and release of 
chlamydial progeny in the cellular environment (Rockey & Matsumoto, 2000) by 
either cell lysis or even a sort of budding. 
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FIGURE 2. Schematic representation of the chlamydial developmental cycle. Infectious but metabolically inactive EBs enter the 
host-cell membrane via endocytosis; EBs transform into the replicative and metabolically active RBs; RBs multiply and then 
redifferentiate into EBs, which are released by the host-cell mostly via lysis. 
EBs, about 300 nm in diameter, are found outside of the host cell and are 
adapted to extracellular survival, they are also metabolically inactive because their 
DNA is highly condensed and surrounded by basic histone-like proteins (Hc-1 and 
Hc-2). EB in fact represents the infectious form, which is able to begin a new 
replicative cycle (Dautry-Varsat et al., 2005). 
The replication cycle begins when an EB adheres to a host cell. The adhesion 
to the host cell can be divided into two phases, the first one reversible and the second 
irreversible (Moulder, 1991; Dautry-Varsat et al., 2005). While in many 
microorganisms, the reversible phase is generally mediated by interactions with 
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glycosaminoglycans on the host cell surface, Chlamydiae appear to use a unique mode 
of attachment in which a glycosaminoglycan (specifically heparan-sulfate) is also 
located on the surface of the bacterium thus working as a bridge (Zhang & Stephens, 
1992). Nevertheless, Chlamydiae should be able to utilise multiple means of entry 
since treatments to inactive the glycosaminonglycans on the chlamydial surface do not 
lead to a complete attachment inhibition (Rasmussen-Lathrop et al., 2000; 
Wupperman et al., 2001). In any case, the interaction between EBs and the 
cytoplasmic membrane is not casual, but occurs in correspondence of specific areas or 
lipid microdomains called rafts (Stuart et al., 2003). The rafts have a high content of 
cholesterol and glycosphingolipids, but contain a limited number of proteins. 
If we consider the pear-shaped EBs of C. pneumoniae as a model, they are able 
to facilitate the adhesion by creating contact points on the host cell and favouring the 
formation of protrusions of its cell wall (Miyashita et al., 1993). The infectious particle 
is then internalised into the host cell, by a process of phagocytosis (endocytosis) in a 
specialised vacuole called phagosome, which in turn is formed by an invagination of 
the cytoplasmic membrane (Rockey & Matsumoto, 2000). 
In the course of the intracellular cycle, EBs are confined within a phagosome, 
and then they are transported in a perinuclear location where they aggregate by means 
of a Ca2+-dependent mechanism. In this way, a series of events occur that are 
fundamental to the survival of the bacterium such as the inhibition of phagosomal 
membrane fusion and remodelling of the inclusion membrane in order to favour the 
passage of nutrients, lipids and metabolites from the host cell cytoplasm. The 
inhibition of phagosomal membrane fusion and the control of the processes described 
above require de novo protein synthesis by Chlamydiae (Hackstadt et al., 1997). EBs, 
therefore, are able to evade the primary defence mechanism of the cell, because they 
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inhibit the phagosome-lysosome fusion by mechanisms not yet understood 
(Kaukoranta-Tolvanen, 1996; Hogan et al., 2004). 
After about 10-12 hours after infection, EBs initiate the synthesis of nucleic 
acids and proteins, gradually increasing in diameter (from 0.6 µm to 1 µm) and 
transforming rapidly into larger forms called RBs. RBs are responsible for the 
intracellular replication (Kaukoranta-Tolvanen, 1996). The transformation of EBs into 
RBs involves a reduction in the number of disulfide bonds existing in the complex of 
the outer membrane, decondensation of the genome and beginning of the synthesis of 
mRNA and proteins. 
RBs, metabolically active, are transported via a dynein-dependent mechanism 
in the proximity of the Golgi apparatus and replicate by binary fission. Some RBs after 
a certain number of divisions are redifferentiated into EBs. As the inclusion size 
increases, the number of EBs increases as well, and they localise generally near the 
edge of the inclusion. In this way, the inclusion contains three different types of bodies: 
reticulate, intermediate (a form of transition) and elementary. It could happen that 
within the same infected cell, there may be multiple inclusions arranged around the 
nucleus, similar to a string of pearls, but this is a peculiar characteristic of 
C. pneumoniae. 
The replication cycle is completed when a new generation of EBs is released. 
The release of new EBs is generally accompanied by the host cell lysis. The duration 
of the replicative cycle depends on the nature of the host cell, but generally is about 
48-72 hours (Kaukoranta-Tolvanen, 1996). 
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1.6 The chlamydial persistence 
As previously mentioned, Chlamydiae have a unique replication cycle wherein 
the microorganism alternates two functionally and morphologically distinct forms: EB 
and RB (Matsumoto, 1988; Rockey & Matsumoto, 2000). However, it has been 
demonstrated that, during the replicative cycle, Chlamydiae can give rise to persistent 
forms (Figure 3) that are non-infectious, non-replicating and metabolically inactive 
(Beatty et al., 1994; Wolf et al., 2000; Hogan et al., 2004; Peters et al., 2005). 
Ultrastructural analysis showed that the replicative cycle is stopped to the state 
of RB prior to its reorganisation into EB. Therefore, there is no host cell lysis and 
formation of new infectious progeny (Beatty et al., 1994; Mehta et al., 1998; 
Wiedeman et al., 2005). 
 
FIGURE 3. Schematic representation of the chlamydial developmental cycle showing that in the presence of IFN-γ, penicillin G 
or other stressful conditions, Chlamydiae give rise to non-infectious persistent forms, which may be reactivated following stress 
removal (Di Pietro et al., 2013e). 
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At a morphological level, the observation by light microscopy with direct 
immunofluorescence methods, showed smaller inclusions (Beatty et al., 1994; Wolf 
et al., 2000; Gieffers et al., 2004) which may have a lower fluorescence intensity 
compared to the replicative form (Goellner et al., 2006), although other authors 
reported larger pleomorphic inclusions (Gussmann et al., 2008; Kokab et al., 2010). 
Several ultrastructural studies, carried out by electron microscopy (Figure 4), showed 
that the inclusions of the persistent form contain, with respect to the replicative form, 
fewer RBs. These RBs, however, appear to be of a greater size (even up to 10 times), 
with a pleomorphic shape and a less electron-dense cytoplasm (Beatty et al., 1994; 
Mehta et al., 1998; Wolf et al., 2000). In some cases, these RBs, which are usually 
defined “aberrant”, arbour electron-dense vesicles of uncertain origin and function, 
located mostly close to their plasma membrane (Wolf et al., 2000). 
 
FIGURE 4. Electron micrographs of C. trachomatis-infected cells showing: (A) a typical inclusion containing EBs and RBs; (B) 
an inclusion containing enlarged, atypical RB forms resulting from penicillin G treatment (Skilton et al., 2009 licensed under the 
terms of the Creative Commons Attribution License). The scale bar represents 4 µm. 
Several in vitro studies have reported a wide range of factors that can induce 
the formation of a persistent form (Beatty et al., 1994; Hogan et al., 2004). In 
particular, it has been shown that Chlamydiae may give rise to persistent forms as a 
result of depletion of essential nutrients such as iron, or following treatment with 
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antibiotics such as penicillin G or even after treatment with certain cytokines such as 
interferon-gamma (IFN-γ). It has also been highlighted the presence of persistent 
forms of C. pneumoniae after the establishment of continuously infected epithelial cell 
lines (a so-called model of spontaneous persistence). Furthermore, Chlamydiae in 
monocyte and macrophage cultures has the features of a persistent infection (Arienne 
et al., 1999; Mannonen et al., 2004; Beagley et al., 2009; Bellmann-Weiler et al., 
2010). The latter evidence is particularly intriguing, because Chlamydiae are thought 
to use monocytes as a means of transport from the initial site of infection to distant 
anatomical districts. 
In addition, it has been shown for the first time by Deka and co-workers (2006) 
that even coinfection conditions may give rise to persistence, when C. trachomatis 
infected cells were coinfected with HSV-2. More interestingly, it has been 
demonstrated later that defective viral particles are enough to trigger chlamydial 
persistence (Deka et al., 2007), and it is estimated that HSV-2 generates 50-200 
defective particles per plaque forming unit. 
The persistent forms, regardless of their inducing factor, retain a number of 
common features such as an aberrant morphology, a loss of infectivity, an altered gene 
expression pattern, a lesser susceptibility to antibiotics and finally a spontaneous 
reactivation after removal of the inducer (Gieffers et al., 2001; Wiedeman et al., 2005). 
Regarding the gene expression pattern of persistent forms, the first molecular 
studies carried out prior to the sequencing of the whole genome of C. trachomatis, 
were restricted to the expression of MOMP and HSP60. These studies have shown that 
exposure to IFN-γ of C. trachomatis resulted in a down-regulation of MOMP and an 
up-regulation of HSP60 (Hogan et al., 2004). 
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Since then, several studies have investigated the transcriptional profile of the 
persistent chlamydial form in different in vitro persistence models, showing a complex 
and inconsistent situation, with only a few genes having a relatively uniform 
expression pattern (Hogan et al., 2004; Goellner et al., 2006; Maurer et al., 2007; Klos 
et al., 2009; Timms et al., 2009; Di Pietro et al., 2012). 
Table II reports the current state of the art about the transcriptional profile of 
in vitro persistent Chlamydiae. Therefore, without a unique transcriptional profile, it 
is unlikely that the persistent form could be a genetically-defined state. It has been 
proposed that it is rather a mid-cycle arrest during the development (Maurer et al., 
2007). Thus, it could be a complex and flexible metabolic strategy designed to favour 
a long-time survival in the host cell by evading the immune response, since several 
genes involved into the energy metabolism are up-regulated during the persistent state 
and some studies have suggested that Chlamydiae are capable of independently 
producing energy (Di Pietro et al., 2013c). 
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TABLE II. Comparison of Chlamydiae gene expression patterns during persistence (Di Pietro et al., 2013c). * proteomic analysis 
** reactivated culture † up-regulated at 12 h p.i. 
   Persistence Genes (+ up regulation; ‒ down regulation; = unchanged) 
Authors Strain Cells Inducer omp
A 
omc
B 
hctA hctB polA dna
A 
mut
S 
ftsK ftsW groE
L 
htrA 
Byrne et al., 2001 C. pneumoniae TW-183 HEp-2 INF-γ     = = = ‒ ‒   
Mathews et al., 2001 C. pneumoniae IOL-207 HEp-2 INF-γ + =        =  
Nicholson et al., 2002 C. trachomatis D n/a Penicillin G =   ‒  = + + = = + 
Belland et al., 2003 C. trachomatis D HeLa INF-γ (24 h) ‒ ‒ ‒ ‒ ‒ ‒ ‒ = ‒ = ‒ 
Belland et al., 2003 C. trachomatis D HeLa INF-γ (48 h**) + = + + = ‒ ‒ = ‒ = = 
Hogan et al., 2003 C. pneumoniae TW-183 HEp-2 Continuous infection + +      =  =  
Slepenkin et al., 2003 C. pneumoniae CM-1 HEp-2 INF-γ + +      ‒  +  
Goellner et al., 2006 C. psittaci HEp-2 INF-γ ‒ ‒† ‒      ‒ ‒  
Goellner et al., 2006 C. psittaci HEp-2 Iron depletion = ‒ ‒      ‒ =  
Goellner et al., 2006 C. psittaci HEp-2 Penicillin G + ‒ ‒      ‒ =  
Mukhopadhyay et al., 2006 C. pneumoniae A-03 HEp-2 INF-γ* + ‒        + + 
Mukhopadhyay et al., 2006 C. pneumoniae A-03 HEp-2 Iron depletion* + =        + + 
Polkinghorne et al., 2006 C. pneumoniae A-03 HEp-2 INF-γ  +      ‒ + ‒ + 
Maurer et al., 2007 C. pneumoniae CWL-029 HEp-2 Iron depletion = ‒ = ‒ = =  = = = + 
Huston et al., 2008 C. trachomatis L2 HEp-2 INF-γ*           ‒ 
Huston et al., 2008 C. trachomatis L2 HEp-2 Penicillin G*           + 
Klos et al., 2009 C. pneumoniae CWL-029 HeLa INF-γ     =   ‒ ‒ +  
Klos et al., 2009 C. pneumoniae CWL-029 HeLa Iron depletion     ‒   = ‒ ‒  
Klos et al., 2009 C. pneumoniae CWL-029 HeLa Penicillin G     ‒   ‒ ‒ ‒  
Timms et al., 2009 C. pneumoniae A-03 HEp-2 INF-γ ‒ ‒  ‒    ‒  ‒ + 
Timms et al., 2009 C. pneumoniae A-03 HEp-2 Iron depletion ‒ ‒  ‒    ‒  ‒ + 
Kokab et al., 2010 C. trachomatis E HEp-2 INF-γ =       ‒ +   
Di Pietro et al., 2012 C. pneumoniae AR-39 HEp-2 Penicillin G ‒  ‒ ‒      ‒ + 
 
Moreover, another unanswered question about chlamydial persistence is 
whether it could be responsible for the latent chronic chlamydial infections reported in 
vivo. Although, the aberrant persistent forms have been identified even in vivo, the link 
between them and the physiopathology of chronic inflammatory infections is still 
controversial (Beatty et al., 1994; Hogan et al., 2004; Wyrick, 2010) mainly because 
the limitations of current diagnostic methods. In fact, we do not have any effective 
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methods to quantise persistence forms in vivo so we cannot correlate them to the 
inflammatory response. This is because quantitative real-time PCR (qRT-PCR) cannot 
discriminate between DNA from replicative and persistent chlamydial forms, and if 
we wanted to look for mRNA instead we could not have any reliable persistence 
marker. Immunological methods are useless and transmission electron microscopy 
(TEM), the gold standard for persistent forms identification, is clearly not suitable for 
quantisation. However, if it was the case, the immunopathogenic antigen HSP60 could 
certainly contribute to the chronic inflammation which characterises the latent chronic 
chlamydial infections and their sequelae. 
1.7 The paradox of peptidoglycan 
As previously stated, Chlamydiae lack detectable peptidoglycan (PG) and the 
structural integrity of the cell envelope appears to be provided by a network of 
disulfide cross-linked proteins associated with the outer membrane. Nevertheless, 
many in vitro studies have described the developmental of chlamydial persistent forms 
after exposure to beta-lactam antibiotics such as penicillin G, thus suggesting a 
predominant role of PG in RB development. Indeed, it is well documented that 
penicillin typically acts by blocking PG biosynthesis through interaction with 
penicillin-binding proteins. 
Although Chlamydiae do not synthesize PG, genome sequencing has revealed 
that these pathogens appear to contain a nearly complete set of genes encoding the 
enzymes for PG biosynthesis (McCoy & Maurelli, 2006; Pavelka, 2007), several of 
which are known to be expressed during the growth cycle. However, the PG 
biosynthetic pathway does not seem to be complete and some enzymes such as 
glycosyltransferases, required for the construction of the linear glycan chains 
(Ghuysen & Goffin, 1999), are missing. 
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To date several hypothesis regarding the presence of an unusual cell wall in 
Chlamydiae have been proposed such as that Chlamydiae possess a unique penicillin-
sensitive PG that has escaped detection because it contains a carboxylated sugar other 
than muramic acid, or the chlamydial penicillin-binding proteins have a vital function 
in chlamydial replication unrelated to the transpeptidation (Moulder, 1993). Two of 
these hypotheses have gained consensus and support over the years, at least to a certain 
extent. 
The first proposes that Chlamydiae synthesize PG strictly during cell division. 
In support of this idea, Brown and Rockey (2000) isolated antibodies, directed against 
a non proteinaceous antigen, called SEP (septum), that recognised an apparent division 
septum of Chlamydiae. In particular, these antibodies localise to a ring-like structure 
within or between developing RBs, reminiscent of FtsZ rings observed in most 
bacteria, whereas in Escherichia coli they localise on the entire cell wall, suggesting a 
structural affinity to the usual PG-containing cell wall. 
The second hypothesis even more intriguing suggests that fragments of PG, 
called muropeptides, are delivered into the host cell cytosol and recognised by the host 
innate immune system. Consistent with this hypothesis, some studies (Opitz et al., 
2005; Welter-Stahl et al., 2006) have demonstrated the recognition of intracellular 
Chlamydiae by Nod1 (nucleotide binding oligomerization domain protein), a cytosolic 
receptor belonging to the PRR family (Pattern Recognition Receptor) of the innate 
immune system. Nod1 has the ability to detect fragments of PG containing meso-
diaminopimelic acid (m-DAP), and then activate the secretion of pro-inflammatory 
cytokines. 
Chlamydiae, like certain pathogenic bacteria, may employ the type III secretion 
system to translocate muropeptides directly into host cell cytosol and trigger an 
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inflammatory response. Regarding m-DAP, it is located at the third position of the 
pentapeptide in the PG of all Gram-negative and some Gram-positive bacteria and it 
plays a pivotal role in PG biosynthesis by cross-linking PG glycan chains to provide 
strength and rigidity. Interestingly, a recent study has revealed that Chlamydiae would 
be able to synthesize m-DAP (McCoy et al., 2006) through an alternative metabolic 
pathway characterised initially only in plants and in cyanobacteria (Hudson et al., 
2006; Hudson et al., 2008; Liu Y et al., 2010) where m-DAP is used for lysine 
biosynthesis (instead Chlamydiae obtain lysine from the host cell). In particular, the 
ct390 gene from C. trachomatis was shown to encode an L,L-diaminopimelate 
aminotransferase (L,L-DAP-AT), that is the main enzyme of this pathway because it 
converts tetrahydrodipicolinate to L,L-diaminopimelic acid, the precursor of m-DAP. 
In addition, the biochemical characterization and crystal structure of C. trachomatis 
L,L-DAP-AT have been recently reported (Watanabe et al., 2011). Moreover, the 
presence of such a gene in Chlamydiae should not surprise because the ancestral 
Chlamydiae may have participated in the events that led to the formation of the plant 
lineages, thus they might be related to the cyanobacterium-chloroplast lineage (Everett 
et al., 1999b; Brinkman et al., 2002). 
In this context, we obtained a relevant result while studying the expression 
profile of relevant genes for chlamydial metabolism in order to find a reliable marker 
of persistence in C. pneumoniae (Di Pietro et al., 2012). We used the in vitro model of 
penicillin G mediated persistence since this persistence model is directly linked to the 
PG biosynthesis and in addition, it may simulate treatment failure of chronic infections 
in vivo. Notably the cp0259 gene of C. pneumoniae, homologous of the ct390 gene of 
C. trachomatis, is up-regulated (Figure 5) during penicillin-induced persistence (Di 
Pietro et al., 2013b), whereas some authors did not find significant up-regulation with 
other persistence inducers such as iron depletion and interferon γ (Belland et al., 2003; 
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Maurer et al., 2007). Thus, it is clear that the up-regulation of the gene encoding 
L,L-DAP-AT, probably aimed to counteract the effects of the penicillin G, remarks 
the physiological importance of the synthesis of peptidoglycan or peptidoglycan-like 
molecules in Chlamydiae. 
 
FIGURE 5. cp0259 expression levels of C. pneumoniae AR 39 (ATCC 53592) determined by quantitative reverse transcription 
PCR (RT-qPCR) at 24 and 72 hours post infection, in cell monolayers (HEp-2 ATCC CCL 23) grown in 24-well culture plates 
(4.0 x 105 cells/well) infected at MOI 30 and treated with penicillin G 500 U/mL (Di Pietro et al., 2013b). The relative expression 
ratios were normalised with the rRNA 16S gene (Pfaffl’s algorithm) and the results are shown as treated / untreated ratio. The 
sequence of primers used to amplify cp0259 were as follow (5'-3'): forward ACATTGCCCACATTACAGGAATCCGCG and 
reverse GCAAGGCGCATGCCAGTAAAGCC (amplicon size 340 bp). * p < 0.05 
1.8 Chlamydia-associated pathologies 
To date, three species of Chlamydiae are of medical interest: C. trachomatis, 
C. pneumoniae and C. psittaci. Notably, despite the relevant set of common features 
discussed previously, Chlamydiae are actually able to cause a broad spectrum of 
diseases. C. trachomatis serovars A to C lead to trachoma, the leading cause of 
preventable blindness in developing countries, while serovars D to K are responsible 
for the majority of sexually transmitted diseases (STDs) all over the world. 
C. trachomatis serovars L1 to L3 of the biovar LGV, have the exclusive ability to pass 
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through epithelia and then to disseminate to and destroy lymphatic tissue by causing 
lymphogranuloma venereum (Mabey & Peeling, 2002). C. pneumoniae is a 
widespread respiratory pathogen that causes sinusitis, pharyngitis and pneumonia. The 
infections are often asymptomatic and the exposure to C. pneumoniae is extremely 
common; epidemiological studies indicate that anti-C. pneumoniae antibody 
prevalence is 50% by the age of 20 and increases with increasing age (Grayston, 2000). 
C. psittaci is the causative agent of psittacosis, a severe zoonotic pneumonia that can 
be considered as an occupational disease. 
More importantly, these pathogens may cause chronic sequelae that according 
to several authors are due to in vivo persistent infections and the consequently 
induction of a chronic inflammatory state. Indeed, C. trachomatis infections may lead 
to ectopic pregnancy, obstructive infertility, reactive arthritis (Reiter’s syndrome) and 
its involvement has been recently suggested in the pathogenesis of chronic intestinal 
diseases (Dlugosz et al., 2011). C. pneumoniae infection may lead to atherosclerosis, 
although relevant and suggestive this correlation is still a matter of debate (Deniset & 
Pierce, 2010; Rosenfeld & Campbell, 2011). C. pneumonaie has been associated, even 
though in a weaker manner, also with the exacerbation of chronic obstructive 
pulmonary disease (COPD) (Papaetis et al., 2009), multiple sclerosis (Pawate & 
Sriram, 2010) and Alzheimer’s disease (Shima et al., 2010). More recently, 
C. pneumoniae has been linked to the osteoporosis related bone loss (Di Pietro et al., 
2013a). Lastly, C. psittaci infection has been associated with ocular adnexal mucosa-
associated lymphoid tissue (MALT) (Collina et al., 2012). 
Chlamydiae are susceptible to antibiotics that interfere with DNA and protein 
synthesis, including tetracyclines (such as tetracycline and doxycycline), macrolides 
(such as erythromycin and azithromycin) and fluoroquinolones (such as ciprofloxacin, 
ofloxacin and levofloxacin), which are the compounds that have been most extensively 
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used for treatment of human infections (Hammerschlag & Kohlhof, 2012). Instead, the 
entire class of beta-lactams is not suitable for Chlamydiae treatment. Nevertheless, as 
previously discussed, it is not appropriate to say that Chlamydiae are not sensitive to 
these antibiotics because they are able to induce persistence. 
However, despite the treatments available, therapeutic failures have been 
reported, presumably due to subinhibitory drug concentrations or reduced chlamydial 
sensitivity. The reduced chlamydial sensitivity has been linked to two phenomena, the 
chlamydial persistence and the emergence of bacterial resistance mediated by different 
types of mutations (Sandoz & Rockey, 2010). Thus, it is important to find out new 
compounds effective against Chlamydiae. 
To this regard, medicinal plants represent a potential reservoir of several 
antimicrobial molecules. In fact, a number of studies, mainly concerning 
C. pneumoniae, have demonstrated antichlamydial activity for a few natural 
polyphenolic compounds (Yamazaki et al., 2003; Alvesalo et al., 2006; Salin et al., 
2010; Salin et al., 2011). 
1.9 The involvement of C. pneumoniae in atherosclerosis 
Atherosclerosis, responsible for about 50% of deaths in developed countries, is 
a disease that affects the intima and the media of large arteries and is characterised by 
the presence of atheromatous plaques (Ross, 1993). It has been shown that 
atherosclerosis is a chronic multifactorial inflammatory disease, determined by the 
interaction between different cell types and effectors such as endothelial cells, smooth 
muscle cells, monocytes / macrophages and inflammatory mediators. The process of 
atherogenesis begins in response to the vessel wall damage (according to the response-
to-injury hypothesis) by endothelial dysfunction and progresses with the formation of 
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a plaque, which in turn reduces, in part or completely, the lumen of the artery (Figure 
6). This can lead to ischemia of the heart, brain or extremities, thus resulting in 
infarction (Ross, 1999). 
 
FIGURE 6. Micrograph of an artery (Masson’s trichrome stain) that supplies the heart with significant atherosclerosis and marked 
luminal narrowing (photo by Nephron published on Wikipedia, licensed under the terms of the Creative Commons Attribution 
License). 
The classical risk factors for atherosclerosis, which may account to the 
endothelial dysfunction, such as dyslipidemia, hypertension, diabetes, tobacco 
smoking and a sedentary lifestyle, can explain only about 40-50% of the 
cardiovascular events. For several years, the focus has turned to the possible link 
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between infection and atherosclerosis, since different experimental evidences have 
shown that the inflammation characterising the pathogenesis of atherosclerosis has 
much in common with that induced by microbial chronic infections (Ross, 1999). 
For this reason, in addition to the traditional cardiovascular risk factors, in the 
last three decades, several infectious agents such as cytomegalovirus, Helicobacter 
pylori, periodontal pathogens and C. pneumoniae have been implicated in the 
pathogenesis of atherosclerosis (Campbell & Kuo, 2004; Rosenfeld & Campbell, 
2011). C. pneumoniae has been considered as the most plausible additional risk factor 
for atherosclerosis, since it has been isolated in a viable form in the atherosclerotic 
plaque, and is able to multiply and persist within vascular cells and to induce the 
chronic inflammatory state underlying atherosclerosis (Schoborg, 2011). 
The first suggestion that C. pneumoniae may be associated with atherosclerotic 
cardiovascular diseases (CVDs) was proposed in 1988 by Saikku and colleagues. They 
showed that patients with acute myocardial infarction and chronic heart disease had 
more frequently anti-C. pneumoniae antibodies than controls. Since then, several 
studies (cross-sectional, case-control, or retrospective) have confirmed the association 
between serological evidence of C. pneumoniae infection and CVDs although others 
(prospective studies) have failed to demonstrate such association (Boman & 
Hammerschlag, 2002; Jha et al., 2008; Swierszcz et al., 2012; Joshi et al., 2013). The 
main limitation of these studies is the difficulty to identify differences in seropositivity 
between patients and controls, since a large part of the population has pre-existing IgG 
antibodies from previous exposure (Dowell et al., 2001). 
Further evidence that C. pneumoniae might play a role in atherosclerosis came 
from studies by the direct detection of antigens and nucleic acids (Watson & Alp, 
2008). In particular, C. pneumoniae has been isolated from atherosclerotic plaques in 
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a viable form (Ramirez, 1996; Jackson et al., 1997) and it has been found by several 
investigators in PBMCs of patients with atherosclerotic cardiovascular diseases 
(Watson & Alp, 2008) so that C. pneumoniae in PBMCs is considered as a marker of 
current persistent infection. Moreover, C. pneumoniae is able to disseminate through 
the host via the infection of monocytes and macrophages, in which is also able to 
establish a persistent infection (Arienne et al., 1999; Bellmann-Weiler et al., 2010). In 
fact, it has been recently demonstrated that C. pneumoniae hides inside apoptotic 
neutrophils to infect macrophages, so it can propagate further (Rupp et al., 2009). 
Therefore, in recent years, four large-scale randomised clinical trials 
(WIZARD, ACES, PROVE IT-TIMI and CLARICOR) have been undertaken to 
demonstrate long-term benefits in patients with cardiovascular diseases and 
undergoing antichlamydial antibiotic treatment (O’Connor et al., 2003; Cannon et al., 
2005; Grayston et al., 2005; Jespersen et al., 2006), but none of them showed a 
reduction in cardiovascular events. However, the failure of the secondary prevention 
trials is not enough to rule out a role of C. pneumoniae in the pathogenesis of 
atherosclerosis. In fact, the results of these studies may have been affected by several 
factors including the refractoriness of chlamydial chronic infections to antibiotic 
treatment and the enrolment of patients with advanced coronary artery diseases 
(Yamaguchi et al., 2003; Deniset & Pierce, 2010; Rosenfeld & Campbell, 2011). On 
the other hand, a very recent clinical trial has showed a positive association between 
the anti-C. pneumoniae therapy and the secondary prevention of cardiovascular events 
(Dogra, 2012). 
Nevertheless, we cannot ignore that the association between C. pneumoniae 
and atherosclerosis is also supported by numerous in vivo and in vitro studies (Belland 
et al., 2004; Watson & Alp, 2008; Sessa et al., 2009). Firstly, most of the animal-
model studies have demonstrated that C. pneumoniae infection could initiate (Fong 
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et al., 1997) or accelerate the progression of the atherosclerotic lesion (Blessing et al., 
2001). Moreover, the atherogenic effect appears to be restricted to C. pneumoniae 
because other microorganisms are not able to induce a similar effect (Kalayoglu et al., 
2002). Secondly, several in vitro studies have shown that C. pneumoniae infection, as 
well as promoting the production of pro-inflammatory cytokines and other pro-
atherogenic factors, may play a role in all the stages of the atherosclerotic lesion 
development, from the initial lesion to the plaque rupture and the thrombus formation, 
which is responsible for the acute cardiovascular event (Watson & Alp, 2008). 
In particular, it has been demonstrated that C. pneumoniae is able to promote 
the accumulation of low-density lipoproteins (LDL) into macrophages, at least in part, 
by affecting the Peroxisome Proliferator-Activated Receptors (PPARs), which are 
fundamental regulators of macrophage lipid homeostasis (Mei et al., 2009; Liu W 
et al., 2010). Furthermore, C. pneumoniae has been shown to induce LDL oxidation 
(oxLDL) by stimulating the production of reactive oxygen species (ROS) (Deby-
Dupont et al., 2005) so that oxLDL were internalised by macrophage scavenger 
receptors leading to foam cell formation (Kalayoglu et al., 1999). 
Infection of monocytes with C. pneumoniae increases also the adherence of 
infected monocytes to endothelial cells. Furthermore, the multiplication of 
C. pneumoniae inside monocytes and macrophages triggers the production of pro-
inflammatory cytokines such as IL-1α, IL-6, tumor necrosis factor (TNF)-α and IL-12. 
Infection of endothelial cells with C. pneumoniae promotes the expression of adhesion 
molecules such as endothelial leukocyte adhesion molecule (ELAM)-1, intercellular 
cell adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1, 
chemokines such as monocyte chemoattractant protein (MCP)-1 and cytokines (IL-1, 
IL-8, TNF-α). It also triggers vascular smooth muscle cells (VSMCs) proliferation 
through induction of human HSP60 and platelet-derived growth factor (PDGF). There 
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is also evidence that C. pneumoniae stimulates endothelial pro-coagulant activity 
through IL-6, IL-8 and plasminogen activator inhibitor. Lastly, the stimulation of 
matrix metalloproteinases (MMPs) may both contribute to the VSMCs migration and 
to the plaque rupture. 
Taken together, the cellular events on vascular wall (as deduced from in vitro 
studies) are intricate and involve several regulatory proteins and enzymes (Munzel 
et al., 2010; Chen & Keany, 2012). These events are summarised in Figure 7 (Di Pietro 
et al., 2013e). 
 
FIGURE 7. Schematic representation of the cellular events linking C. pneumoniae infection to the atherosclerotic lesion 
development (Di Pietro et al., 2013e). In platelets, C. pneumoniae contributes to platelet activation and aggregation. In endothelial 
cells, C. pneumoniae leads to endothelial dysfunction and induces an increased surface expression of human HSP60 (hHSP60). 
In macrophages, C. pneumoniae induces the oxidation of LDL and the uptake of oxidised LDL (oxLDL), leading to foam cell 
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formation. Moreover, chlamydial HSP60 (cHSP60) stimulates macrophages to synthetize matrix metalloproteinases (MMPs) 
which degrade the internal elastic lamina of the endothelial wall. In vascular smooth muscle cells (VSMCs), C. pneumoniae 
enhances cell proliferation and migration, which is consequently facilitated by a compromised internal elastic lamina. 
However, we must point out that the first report on the complex profile of acute 
phase reactant proteins induced by acute respiratory infection of mice with 
C. pneumoniae (Campbell et al., 2010) revealed a contradictory situation in which 
both pro- and anti-inflammatory cytokines are produced. In particular, they evidenced 
increased plasma levels of IL-2, IL-5, IL-6, IL-10, IL-12 and IFN-γ but they did not 
find elevated levels of TNF-α, IL-1β and IL-4. In fact, IL-10 has an anti-inflammatory 
effect that may have inhibited the production of TNF-α. Thus, the actual contribution 
of the responses to the chlamydial infection to both acute and chronic inflammatory 
processes remains to be elucidated. 
In any case, given the importance of the foam cells in the evolution of the 
atherosclerotic lesion, researchers have recently focused their attention to antioxidant 
and anti-inflammatory effectors, such as resveratrol and statins. Resveratrol is a natural 
polyphenol, more precisely a stilbenoid, produced by several plants. It is found in the 
skin of red grapes and various fruits but especially in the roots of the Japanese 
knotweed, from which it is extracted commercially. Statins are a class of drugs 
commonly used to lower cholesterol levels by inhibiting the enzyme 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase, which plays a pivotal role in the 
production of cholesterol. These compounds can help the maintenance of lipid 
homeostasis, as well as counteract the oxidative process involved in the pathogenesis 
of cardiovascular diseases (Agarwal et al., 2012; Xu & Si, 2012; Li et al., 2013). 
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2 AIM OF THE STUDY 
Chlamydiae may cause chronic sequelae that according to several authors may 
be related to in vivo persistent forms and the consequently induction of a chronic 
inflammatory state. Chlamydia-associated sequelae are of a great importance for the 
public health since C. pneumoniae infection may be linked to atherosclerosis whereas 
C. trachomatis infection could lead to ectopic pregnancy, obstructive infertility and 
reactive arthritis. Moreover, chlamydial persistent forms are even difficult to treat with 
antibiotics. Thus, we investigated in vitro different aspects of the pathogenesis of 
Chlamydia-associated chronic diseases, including possible treatments. More 
specifically, in C. pneumoniae, we examined the atherogenic process by setting up a 
model of foam cell induction by means of macrophages infection. In this model, we 
studied the production of IL-17A, a cytokine recently reported as proatherogenic 
(Chen et al., 2010), and the protective effects of resveratrol (Di Pietro et al., 2013d), a 
natural polyphenol known to exert antioxidant, cholesterol-lowering and anti-
inflammatory effects. 
In C. trachomatis, we assessed the antichlamydial properties of the essential 
oil extracted from Mentha suaveolens (EOMS) (De Santis et al., 2012), a well-known 
officinal plant, in an effort to find new means for prevention and treatment of 
urogenital and sexually transmitted infections. 
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3 MATERIALS AND METHODS 
3.1 Chemicals 
Resveratrol, Low Density Lipoprotein (LDL), Oil Red O, PPAR-γ antagonist 
(GW9662), Thiazolyl Blue Tetrazolium Bromide (MTT reagent), Thiobarbituric Acid 
(TBA) reagent and other chemicals were from Sigma-Aldrich (St. Louis, MO, USA). 
Fluorescein isothiocyanate (FITC)-conjugated specific antichlamydial LPS 
monoclonal antibody (Pathfinder Chlamydia Culture Confirmation System) was from 
Bio-Rad (Hercules, CA, USA) whereas the antichlamydial MOMP (MicroTrak 
Chlamydia trachomatis Culture Confirmation Test) was from Trinity Biotech (Bray, 
Co. Wicklow, Ireland). IL-17A ELISA kit was from R&D Systems (Minneapolis, MN, 
USA). 
Mentha suaveolens essential oil (EOMS) was kindly provided by the 
Department of Chemistry and Drug Technologies, “Sapienza” University, Rome, Italy. 
It was obtained from wild-type plants grown in Tarquinia forests located around 100 
kilometres from Rome. The oil was extracted as previously described (Angiolella 
et al., 2010), then analysed for chemical composition by gas chromatography and mass 
spectroscopy. The chemical composition analysis revealed that piperitenone oxide 
(PEO) constitutes 77% of EOMS. Alpha cubebene and alpha pharnesene were also 
present, among other minor constituents as reported in Table III. 
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TABLE III. The chemical constituents of the EOMS 
Chemical constituents of EOMS 
eucalyptol 4.90% borneol 0.30% 
3-octanol 2.10% alpha-cubebene 6.00% 
para-cymene 1.03% p-cymenol 0.50% 
alpha-pharnesene 6.10% piperitenone 
oxide 
77.0% 
beta-myrcene 0.86% demelverine 0.60% 
 
3.2 Cell culture, growth and titration of Chlamydiae 
C. pneumoniae strain AR-39 (ATCC 53592) was propagated in Hep-2 cells 
(ATCC CCL-23) in presence of 2 μg/mL cycloheximide. C. trachomatis L2 (ATCC-
VR-902B) was propagated in HeLa cells (ATCC CCL-2) in presence of 1 μg/mL 
cycloheximide. Hep-2 and HeLa epithelial cell lines as well as J774A.1 murine 
macrophages (ATCC TIB-67), were grown in Dulbecco’s Modified Eagle’s medium 
(DMEM) with 4.5 g/L glucose supplemented with 2-10% heat-inactivated fetal calf 
serum (FCS). 
Infected cells were harvested after an incubation of either 72 h 
(C. pneumoniae) or 48 h (C. trachomatis) at 37 °C and 5% CO2 by using cell scrapers 
and vortexed with sterile glass beads for 2 min. After the removal of cell debris by 
centrifugation at 250 × g for 10 min, the supernatant was centrifugated at 20,000 × g 
and 4 °C for 20 min and the pellet was resuspended in sucrose-phosphate-glutamate 
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buffer (SPG buffer) (0.2 M sucrose, 3.8 mM KH2PO4, 6.7 mM Na2HPO4, 5.5 mM 
glutamic acid at pH 7.4) and stored at -70 °C in small aliquots until use. 
The infectious titre (Inclusion-Forming Units [IFU] per mL) was assessed by 
immunofluorescence assay. Briefly, fresh cell monolayers grown in 24-well culture 
plates on glass coverslips, were infected with tenfold serial dilutions of bacterial stock, 
incubated for 48/72 h, washed twice with phosphate-buffered saline (PBS), fixed for 
10 min with methanol, and stained with fluorescein isothiocyanate (FITC)-conjugated 
monoclonal antibody against either chlamydial LPS or C. trachomatis MOMP. The 
total number of IFU was enumerated by counting ten microscope fields using a 
fluorescence microscope (1000X magnification). 
3.3 Cytotoxicity assays 
The cytotoxic effect of resveratrol and EOMS was determined by the MTT 
method (Thiazolyl Blue Tetrazolium Bromide) which measures the activity of living 
cells via mitochondrial dehydrogenases. Macrophages (1.0 x 104 cells per well) were 
incubated with resveratrol at various concentrations (0, 25, 50 and 100 µM) for 48 h. 
HeLa cells (1.0 x 104 cells per well) were incubated with twofold serial dilutions of 
EOMS (0.5 mg/mL; 0.25 mg/mL; 0.125 mg/mL; 64 μg/mL; 32 μg/mL; 16 μg/mL; 
8 μg/mL; 4 μg/mL; 2 μg/mL; 1 μg/mL). 10% in volume of MTT reagent (5 mg/mL) 
was added to each well and incubated for additional 2 h. Afterwards, the medium was 
removed and MTT crystals were dissolved with the MTT Solubilisation Solution 
(0.1 N HCl in isopropanol). The amount of formazan produced was detected by 
measuring the absorbance at 570 nm (ELISA Reader). The cytotoxic effect of 
resveratrol and EOMS on cells were expressed as percent cell viability compared to 
the control cells. 
 35 
 
3.4 C. pneumoniae, foam cells and resveratrol 
3.4.1 Anti-chlamydial assay of resveratrol 
To evaluate the antichlamydial effect of resveratrol, J774A.1 murine 
macrophages (1.0 x 105 cells per well) were infected with C. pneumoniae at a 
multiplicity of infection (MOI) of 2 as described above. C. pneumoniae-infected 
macrophages were incubated for 72 h in the presence or absence of 25 µM resveratrol. 
Then, macrophages were fixed and stained with FITC-conjugated monoclonal 
antibody against chlamydial LPS as previously described. The percentage of infected 
cells per coverslip was used to evaluate the infectivity of bacteria. 
3.4.2 C. pneumoniae-induced foam cell formation 
J774A.1 murine macrophages (1.0 x 105 cells per well) were infected with 
C. pneumoniae (MOI = 2), then washed with PBS and cultured for 48 h in the presence 
or absence of human LDL (100 μg/mL). Foam cell formation was evaluated by 
Oil Red O staining. 
3.4.3 Effects of resveratrol on C. pneumoniae-induced foam cell formation 
J774A.1 murine macrophages (1.0 x 105 cells per well) were pretreated with 
25 μM resveratrol for 1 h at 37 °C and 5% CO2. Next, cells were washed with PBS, 
infected with C. pneumoniae (MOI = 2), and incubated with LDL (100 μg/mL) in the 
presence or absence of resveratrol (25 μM) for additional 48 h. Control samples were 
also provided with uninfected cells and cells treated only with resveratrol. 
For experiments with the PPAR-γ antagonist, macrophages were pretreated 
with GW9662 (10 μM) at 37 °C and 5% CO2 for 2 h before resveratrol treatment 
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(25 μM). Macrophages were then infected with C. pneumoniae (MOI = 2) and 
incubated with resveratrol (25 μM), GW9662 (10 μM) and LDL (100 μg/mL) for 
additional 48 h. 
3.4.4 Oil Red O staining 
Macrophages were washed twice with PBS, fixed with 10% paraformaldehyde 
for 10 min, stained with 1% Oil Red O solution (60% isopropanol) for 10 min and then 
counterstained with hematoxylin for two min. Cells were washed three times with tap 
water and examined by light microscopy (1000X magnification). The intracellular 
lipid droplets were stained red whereas cell nuclei were stained blue. 
Foam cells, defined as cells with ten Oil Red O-positive lipid droplets or more, 
were quantified and expressed as percentage of positive Oil Red O cells to total cells. 
3.4.5 Lipoprotein oxidation assay 
LDL oxidation was quantified by measuring the levels of malondialdehyde 
(MDA) present as thiobarbituric acid reactive substances (TBARS). 
After 48 h hours of incubation at 37 °C and 5% CO2, cells were collected into 
microfuge tubes and then centrifugated at 1500 × g for 10 min. 400 μL of supernatant 
were incubated with 800 μL of TBARS reagent (0.67% thiobarbituric acid in 0.1 M 
NaOH-trichloroacetic acid, 1:1 ratio), at 95 °C for 30 min. The mixture was cooled 
and centrifuged at room temperature for 10 min at 500 × g, and the absorbance of the 
supernatants was measured at 532 nm in a spectrophotometer. Concentrations of LDL 
oxidation products were determined from a standard curve constructed using 
malondialdehyde (MDA), which reacts with TBA to yield fluorimetric MDA-TBA 
adducts. Oxidation values were expressed as nmol MDA/mL. 
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3.4.6 IL-17A measurement 
IL-17A levels in the supernatants stored at -20 °C were measured by using a 
commercially available ELISA kit according to the manufacturer’s instructions. 
3.5 Antimicrobial activity of EOMS against C. trachomatis 
3.5.1 Susceptibility testing after EOMS exposure 
Semi-confluent HeLa monolayers (2.0 x 105 cells), grown in 24-well (with 
glass coverslips) culture plates, were infected with C. trachomatis at a multiplicity of 
infection (MOI) of 0.05 by centrifugation at 900 × g at 37 °C for 1 h. The inoculum 
was then aspired and fresh medium (the infection-medium), with or without EOMS, 
was added. Infected HeLa monolayers were incubated at 37 °C in a 5% CO2 
atmosphere for 48 h. The cell monolayers were stained with a FITC-conjugated 
monoclonal antibody and the inclusions were counted as described above. 
3.5.2 Infectivity yield testing after EOMS exposure 
To assess the infectivity of chlamydial elementary bodies after 48 h exposure 
to EOMS, infected HeLa monolayers grown on 24-well culture plates were disrupted 
as described above and repassaged onto fresh confluent HeLa monolayers, grown on 
glass coverslips. The infected cells were incubated at 37 °C for 48 h. The cell 
monolayers were stained with a FITC-conjugated monoclonal antibody and the 
inclusions were counted as described above. 
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3.5.3 Infectivity yield testing after treatment with EOMS during different stages 
EOMS was added during one of the following stages in different samples: EBs 
suspension pretreatment for 2 h at 37 °C before C. trachomatis inoculation; EBs 
suspension pretreatment for 2 h and C. trachomatis inoculation for 1 h; C. trachomatis 
inoculation for 1 h; C. trachomatis inoculation for 1 h and cell monolayers post-
incubation for 48 h; only cell monolayers post-incubation for 48 h. Infected HeLa 
monolayers were disrupted, repassaged and stained with a FITC-conjugated 
monoclonal antibody as described above. 
3.5.4 Time killing of C. trachomatis EBs by EOMS pretreatment 
EBs suspensions of C. trachomatis were incubated (pretreatment) for 30, 60 or 
120 min at 37 °C in the presence or absence of EOMS at different concentrations 
before inoculating semi-confluent HeLa monolayers grown in 24-well (with glass 
coverslips) culture plates, at a MOI of 0.05 as described above. Infected HeLa 
monolayers were incubated at 37 °C in a 5% CO2 atmosphere for 48 h. The cell 
monolayers were stained with a FITC-conjugated monoclonal antibody and the 
inclusions were counted as described above. 
3.6 Statistical analysis 
Two independent series of experiments were performed in triplicate. The data 
was given as mean ± standard deviation and the P-value was calculated using the 
Student’s t test (p < 0.05 was considered significant). 
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4 RESULTS 
4.1 C. pneumoniae-induced foam cell formation and the effects of 
resveratrol 
First of all, we performed experiments to examine the cytotoxic effect of this 
polyphenol on the cells used. Thus, macrophages were incubated for 48 h with 
resveratrol at various concentrations and cell viability was determined by the MTT 
test. No significant reduction of cell viability or morphological changes were observed 
when macrophages were treated with resveratrol at 25 µM, as reported in Figure 8. 
 
FIGURE 8. Cytotoxicity of resveratrol on J774A.1 murine macrophages. The cell monolayers were treated with different 
concentrations of resveratrol for 48 h. Cytotoxicity was tested by the MTT method. Results were expressed as percentage of 
survival. * p >> 0.05 
As shown in Figure 9, C. pneumoniae infection induced macrophages-derived 
foam cell formation in the presence of high levels of LDL (100 µg/mL). Compared to 
uninfected and LDL-treated macrophages, C. pneumoniae infection significantly 
increased the number of Oil Red O-stained lipid droplets (p = 0.006). By contrast, the 
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treatment with 25 µM resveratrol markedly reduced C. pneumoniae-induced foam cell 
formation (p = 0.03). 
 
FIGURE 9. Resveratrol reduced C. pneumoniae-induced foam cell formation. Foam cells expressed as percentage of positive Oil 
Red O cells compared to total macrophages. Macrophages stained with Oil Red O to detect lipid content, cellular nuclei 
counterstained with haematoxylin (400X magnification). * p < 0.05 vs control; ‡ p < 0.05 vs C. pneumoniae/LDL 
To determine whether the reduction in the number of foam cells were due to an 
antichlamydial activity of resveratrol, C. pneumoniae infected macrophages were 
incubated for 72 h in the presence of this polyphenol (25 µM) and the subsequent 
number of infected cells was determined. There was no significant reduction in the 
number of infected macrophages treated with resveratrol (75% ± 2.3) as compared to 
untreated cells (69% ± 3.1). 
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As previously reported, C. pneumoniae induces foam cell formation partly by 
stimulating LDL oxidation (Kalayoglu et al., 1999). As shown in Figure 10, a 
significantly increased production of TBARS (p < 0.001), expressed as MDA, was 
observed in infected macrophages as compared to uninfected cells. In contrast, in 
presence of resveratrol, the LDL oxidation was significantly inhibited (p = 0.008) as 
shown by the reduction of MDA levels when compared to untreated cells. 
 
FIGURE 10. Resveratrol (25 µM) reduced LDL oxidation induced by C. pneumoniae infection. TBARS produced in culture 
medium, expressed as nmol MDA/mL, after 48 h incubation with LDL (100 µg/mL), C. pneumoniae/LDL, 
C. pneumoniae/LDL/RESV or LDL/RESV. * p < 0.001 vs control; ‡ p < 0.01 vs C. pneumoniae/LDL 
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It has been also reported, that C. pneumoniae induces foam cell formation via 
a PPAR-γ-dependent pathway (Mei et al., 2009). Therefore, we examined whether the 
inhibitory effects of resveratrol on C. pneumoniae induced foam cell formation were 
dependent upon PPAR-γ. The treatment with the PPAR-γ-specific antagonist, 
GW9662 (10 µM), significantly diminished (p < 0.01) the effect of resveratrol 
increasing the intracellular lipid accumulation and therefore the foam cell formation 
(Figure 11). 
 
FIGURE 11. Effect of PPAR-y antagonist on resveratrol-mediated inhibition of foam cell formation. Macrophages were pre-
treated for 2 h with the PPAR-γ antagonist GW9662 (10 µM), before the addition of resveratrol (25 µM), and then further 
incubated for 48 h with resveratrol, GW9662 and LDL (100 µg/mL) in the presence or absence of C. pneumoniae. Foam cells 
expressed as percentage of positive Oil Red O cells compared to total macrophages. * p < 0.01 vs control; † p < 0.01 vs 
C. pneumoniae/LDL; ‡ p < 0.05 vs C. pneumoniae/LDL/RESV 
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Moreover, compared to uninfected and LDL-treated macrophages, 
C. pneumoniae infection significantly increased IL-17A production (p < 0.001). On 
the contrary, IL-17A levels were markedly lower in infected macrophages treated with 
resveratrol (p < 0.01) as compared to untreated cells (Figure 12). 
 
FIGURE 12. Effect of resveratrol (25 µM) on C. pneumoniae-induced IL-17A production. IL-17A levels in supernatants of 
macrophages incubated with LDL (100 µg/mL), C. pneumoniae/LDL, C. pneumoniae/RESV/LDL or LDL/RESV for 48 h were 
measured by ELISA assay. * p < 0.001 vs control; ‡ p < 0.01 vs C. pneumoniae/LDL 
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4.2 Antimicrobial activity of the essential oil of Mentha suaveolens 
against C. trachomatis 
We started by assaying the inhibitory properties of the essential oil of Mentha 
suaveolens (EOMS) against C. trachomatis, by using different concentrations of 
EOMS (up to 64 μg/mL) according to the results of our cytotoxicity assays (Figure 
13). 
 
FIGURE 13. Cytotoxicity of EOMS on HeLa cells. The cell monolayers were treated with different concentrations of EOMS for 
48 h. Cytotoxicity was tested by the MTT method. Results were expressed as percentage of survival. * p = 0.36 
We observed inclusions even at the highest concentration tested (64 μg/mL), 
so we were not able to determine a MIC value as defined as the lowest concentration 
at which no inclusion can be seen. However, we obtained a dose-dependent decrease 
of the average size of the inclusions (Figure 14), without a significant reduction of the 
number of inclusions (data not shown). 
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FIGURE 14. FITC-staining of C. trachomatis infected HeLa cell monolayers (MOI = 0.05) treated for 48 h with different 
concentrations of EOMS: (A) untreated, (B) 16 μg/mL, (C) 32 μg/mL, (D) 64 μg/mL (400X magnification). 
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In order to determine if the EOMS exposure affects the chlamydial infectivity, 
infected cell monolayers were incubated with different concentrations of EOMS for 
48 hours and were repassaged onto fresh cell monolayers. As shown in Figure 15, a 
statistically significant reduction of infectious EBs was observed in the infected cells 
treated with 64 μg/mL EOMS as compared to untreated cells (p = 0.01). 
 
FIGURE 15. Infectivity yield of C. trachomatis-infected HeLa cell monolayers (MOI = 0.05) treated with different 
concentrations of EOMS added during the post-incubation for 48 h. * p < 0.05 
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To investigate in more detail in which stage of the chlamydial development 
cycle the tested compound is able to exert a biological effect, we challenged infected 
cell monolayers with 64 μg/mL EOMS added at different stages separately (from the 
pretreatment to the post-incubation of 48 hours), then we determined the chlamydial 
infectivity as described above. The results shown in Figure 16 indicated that EOMS 
can affect chlamydial infectivity only if is present during the post-incubation of 48 
hours, at least at these concentrations. 
 
FIGURE 16. Infectivity yield of C. trachomatis-infected HeLa cell monolayers (MOI = 0.05) treated with 64 μg/mL EOMS. 
EOMS was added at different stages: (A) EBs suspension pretreatment for 2 h before C. trachomatis inoculation; (B) EBs 
suspension pretreatment for 2 h and C. trachomatis inoculation for 1 h; (C) C. trachomatis inoculation for 1 h; (D) C. trachomatis 
inoculation for 1 h and cells post-incubation for 48 h; (E) cells post-incubation for 48 h. * p < 0.05 vs untreated sample 
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By contrast, in a time killing experiment, as shown in Figure 17, we found that 
after 30 minutes of pretreatment with 2.0 mg/mL EOMS before the cell monolayers 
were inoculated, chlamydial EBs had completely lost their infectivity. We also 
observed a significant infectivity loss with 0.5 and 1.0 mg/mL EOMS (p < 0.05). 
 
FIGURE 17. Time killing of EBs resuspended in the infection medium added with different concentrations of EOMS. After the 
incubation time (at 37 °C) the EBs were used to infect cell monolayers grown on glass coverslips. * p < 0.05 vs untreated sample 
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5 DISCUSSION 
Chlamydiae, a family of obligate intracellular Gram-negative bacteria, cause a 
broad spectrum of diseases in humans. C. pneumoniae is a common agent of 
community-acquired pneumonia and other, generally mild, respiratory tract infections, 
while C. trachomatis is the leading cause of sexually transmitted diseases all over the 
world and of trachoma in developing countries. More importantly, these pathogens 
may lead to severe chronic sequelae. In fact, C. pneumoniae infection have been 
associated to atherosclerosis, whereas C. trachomatis infection may lead to ectopic 
pregnancy, obstructive infertility and reactive arthritis. These sequelae could result 
from the inflammatory state induced by persistent chlamydial infections. 
In our research, we examined the atherogenic process by setting up a model of 
foam cells induction by means of macrophages infection with C. pneumoniae. In this 
model, we studied the production of IL-17A, a cytokine recently reported as 
proatherogenic (Chen et al., 2010), and the protective effects of resveratrol (Di Pietro 
et al., 2013d), a natural polyphenol. 
Indeed, C. pneumoniae association with cardiovascular diseases as well as the 
involvement of this microorganism in the pathogenesis of atherosclerosis, has been 
suggested by numerous studies (Belland et al., 2004; Watson & Alp, 2008; Sessa et al., 
2009). C. pneumoniae may promote the development and progression of the 
atherosclerotic process, whose first step consists in the foam cell formation. In more 
detail, C. pneumoniae is well known to play a causative role in the foam cell formation 
mainly through the stimulation of LDL oxidation as well as the uptake of oxidized 
LDL by macrophages. 
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Our results demonstrate for the first time that resveratrol counteracts the 
C. pneumoniae-induced intracellular lipid and cholesterol accumulation as well as the 
IL-17A production. A relevant decrease in the number of foam cells and IL-17A levels 
was observed in macrophages infected and treated with resveratrol, as compared to 
infected but untreated cells. 
The decreased production of IL-17A and malondialdehyde observed in our 
study suggests that resveratrol prevents the inflammatory response and the LDL 
oxidation induced by C. pneumoniae. Several studies have suggested that resveratrol 
exhibited cardio-protective and anti-inflammatory properties, since this polyphenol 
has been shown to decrease the synthesis of several cytokines including IL-17A 
(Lanzilli et al., 2012; Li et al., 2012) as well as to efficiently contrast the LDL 
oxidation which contributes to the pathogenesis of atherosclerosis. 
It is also well understood that cholesterol efflux through reverse cholesterol 
transporters (ABCA1 and ABCG1) directly contributes to macrophages 
transformation into foam cells (Pennings et al., 2006; Ye et al., 2011). More 
interestingly, it has been recently reported that C. pneumoniae infection down-
regulates the ABCA1/ABCG1 expression via PPAR-γ (Mei et al., 2009). Our results 
reveal that the inhibition of PPAR-γ by a specific antagonist (GW9662), in presence 
of resveratrol and C. pneumoniae, enhanced intracellular lipid accumulation and the 
subsequent foam cell formation. As a matter of fact, GW9662 both simulates 
C. pneumoniae infection and prevents the positive effects of resveratrol by blocking 
the PPAR-γ pathway. 
Particularly intriguing is the effect of resveratrol on IL-17A synthesis. This 
cytokine was first believed to be exclusively produced by a specialised subclass of T 
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cells, but it is now known to be secreted by other innate immune cell types including 
macrophages (Korn et al., 2009; Jha et al., 2011). 
Our results demonstrates, for the first time, the C. pneumoniae-induced 
synthesis of IL-17A by macrophages and provides further evidence on its 
proatherogenic effect. In fact, in our study, it was observed a decrease in the production 
of IL-17A following resveratrol treatment of infected macrophages exposed to LDL, 
along with a lower foam cell formation. These findings are supported by in vivo 
studies, which demonstrated the proatherogenic effects of IL-17A since higher levels 
of IL-17A were associated with C. pneumoniae-induced atherosclerosis (Song & 
Schindler, 2004; Chen et al., 2010). In addition, concerning the proatherogenic 
properties of IL-17A, a recent study demonstrated that this cytokine activates vascular 
cells to secrete other cytokines that in turn enhance foam cell formation (Eid et al., 
2009). 
Another aspect of our research was to assess the antichlamydial properties of 
the essential oil extracted from Mentha suaveolens (De Santis et al., 2012), a well-
known officinal plant widespread in the Mediterranean area. In fact, the emerging 
phenomenon of drug resistance in C. trachomatis as well as persistent chlamydial 
infections, have raised interest in substances of natural origin as a therapeutic 
alternative. Many natural phenols have been shown antichlamydial properties in vitro, 
leading to the hypothesis that polyphenols consumed on a daily basis may have 
prophylactic properties. Moreover, it is well documented the antibacterial activity of 
essential oils (EOs) from some medicinal plants against a broad range of pathogenic 
microorganisms (Reichling, 2009). 
The essential oil of Mentha suoveolens (EOMS) contains a high percentage of 
oxides such as piperitenone oxide (PEO) and piperitone oxide (PO), terpenic alcohols 
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(phenol, p-cymen-8-ol, geraniol, terpineol and borneol) and terpenic ketones 
(pulegone and piperitenone) all of which account for 65% to 90% of the total essential 
oil. 
We demonstrated that EOMS could completely abolish the infectivity of 
C. trachomatis elementary bodies (EBs) if used at concentrations higher than 
1 mg/mL. This may lead to applications in topic products for prevention purposes, in 
this case we can think especially to C. trachomatis genital infections. 
We also found out that EOMS could affect C. trachomatis development cycle, 
if added to the medium of cell-cultures during the post-incubation period, but without 
being able to completely eradicate the microorganism, at least if used at the 
concentrations that can be tolerated by human cells. However, we observed a dose-
dependent decrease of the average size of the inclusions. Subsequent infectivity yield 
tests showed a proportional decrease in chlamydial progeny production. 
Thus, we can also hypothesize a possible application of the EOMS as an 
adjuvant for the antibiotic treatments in order to reduce the risk of developing 
persistent infections, but this of course requires additional investigations. 
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